ETFIQData as of Nov 19, 2026. · etfiq.com/funds/thnr

THNR Fact Sheet: Amplify Weight Loss Drug & Treatment ETF

Share
$24.26
close, Nov 20, 2026

Over the year to Nov 19, 2026, THNR returned −0.1% in total and charged 0.59% a year.

1-year total return
−1.3%
to Nov 20, 2026
Expense ratio
0.59%
a year
Net assets
$4.9m
on Nov 19, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

THNR $9,986 −0.1% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−2.7%
3 months−11.9%
Year to date−3.8%
1 year−1.3%
Since launch−2.0%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Eli Lilly & Co11.94%
Novo Nordisk A/S8.75%
Regeneron Pharmaceuticals Inc6.15%
Amgen Inc6.03%
Gilead Sciences Inc5.91%
Roche Holding AG5.87%
AstraZeneca PLC5.81%
AbbVie Inc5.72%
Chugai Pharmaceutical Co Ltd5.52%
Pfizer Inc5.26%

THNR top ten by weight, 67.0% of the fund, of its 21 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 21 stocks in healthcare innovation and GLP-1, 46% of its weight in S&P 500 companies · First traded May 21, 2024 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, THNR Fact Sheet: Amplify Weight Loss Drug & Treatment ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/thnr/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/thnr.